在无意中再次暴露后,因fexuprazan引起的重复性肝损伤
Sook Jin Seong1, O Seong Kweon2, Young-Ran Yoon1
1Department of Clinical Pharmacology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea.
British journal of clinical pharmacology
|August 20, 2025
概括
费克苏普拉赞是一种与竞争的酸阻断剂,可能导致罕见的,反复的肝损伤. 这一案例凸显了需要仔细监测患者病史, 尤其是那些有潜在代谢问题的人.
科学领域:
- 肝病学
- 药理学
- 胃肠病学
背景情况:
- 费克苏普拉桑是一种与竞争的酸阻断剂,用于胃食道反流症.
- 关于费克苏普拉桑的肝毒性数据有限.
- 药物不良反应需要彻底调查.
研究的目的:
- 报告与fexuprazan相关的药物诱导性肝损伤 (DILI) 的情况.
- 分析fexuprazan引起的肝损伤的临床,生化和组织学特征.
- 强调新药上市后监测的重要性.
主要方法:
- 一位61岁的女性因使用fexuprazan导致的肝损伤.
- 肝脏活检分析显示与DILI一致的特征.
- 在非故意再次暴露于fexuprazan后出现复发.
- 药物动力学分析和药物遗传学测试 (CYP2C19).
主要成果:
- 患者经历了两次肝损伤,生化和组织学发现相似.
- 第二集符合Hy的法律标准,并提高了RUCAM的分数.
- 药物动力学分析表明肝损伤时代谢受损.
- 鉴定出一种 CYP2C19 低代谢基因型,但其作用有限.
结论:
- 费克苏普拉赞可能导致罕见但可重现的特异性肝损伤.
- 在再次暴露后发生了复发性肝损伤,证实了因果关系.
- 这一案例强调了需要对fexuprazan进行警的药物史和营销后监测.
相关概念视频
Desensitization and Tachyphylaxis
2.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.2K
Hepatic Drug Excretion: Enterohepatic Cycling
1.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.7K
Hepatic Drug Excretion: Influencing Factors
216
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
216
Pharmacovigilance
989
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
989
Prevention of Further Absorption of Poison
925
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
925
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274


